Jeffrey A. Rona Net Worth

Mr. Jeffrey A. Rona biography

Jeffrey A. Rona is the Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer at Ovid Therapeutics Inc.

What is the salary of Mr Rona?

As the Principal Financial Officer és Principal Accounting Officer & Chief Bus. and Financial Officer of Ovid Therapeutics Inc, the total compensation of Mr Rona at Ovid Therapeutics Inc is $494,502. There are 6 executives at Ovid Therapeutics Inc getting paid more, with Jeremy Levin having the highest compensation of $3,008,980.

How old is Mr Rona?

Mr Rona is 53, he's been the Principal Financial Officer és Principal Accounting Officer & Chief Bus. and Financial Officer of Ovid Therapeutics Inc since . There are 12 older and 4 younger executives at Ovid Therapeutics Inc. The oldest executive at Ovid Therapeutics Inc is Bart Friedman, 75, who is the Lead Independent Director.

What's Mr Rona's mailing address?

Jeffrey's mailing address filed with the SEC is C/O OVID THERAPEUTICS INC., 441 NINTH AVENUE, NEW YORK, NY, 10001.

Insiders trading at Ovid Therapeutics Inc

Over the last 9 years, insiders at Ovid Therapeutics Inc have traded over $37,290 worth of Ovid Therapeutics Inc stock and bought 2,202,070 units worth $5,624,523 . The most active insiders traders include Pharmaceutical Co Ltdmillen..., Barbara Gayle Duncan és Jeremy M Levin. On average, Ovid Therapeutics Inc executives and independent directors trade stock every 218 days with the average trade being worth of $229,440. The most recent stock trade was executed by Jeremy M Levin on 18 March 2024, trading 18,248 units of OVID stock currently worth $50,364.

What does Ovid Therapeutics Inc do?

ovid therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. ovid’s drug candidate, ov101, is currently in development for the treatment of symptoms of angelman syndrome and fragile x syndrome. ovid is also developing ov935 in collaboration with takeda pharmaceutical company limited for the treatment of rare epileptic encephalopathies. ovid has initiated the phase 2 stars trial of ov101 in adults with angelman syndrome and a phase 1 trial in adolescents with angelman and fragile x syndrome to identify doses suitable for younger patients. review our community guidelines: http://www.ovidrx.com/community-guidelines/

Ovid Therapeutics Inc executives and stock owners

Ovid Therapeutics Inc executives and other stock owners filed with the SEC include:

• Jeremy Levin,
  Chairman of the Board, Chief Executive Officer
• Amit Rakhit,
  President, Chief Medical Officer
• Dirk Haasner,
  Senior Vice President - Global Regulatory Affairs
• Timothy Daly,
  Executive Vice President - Finance, Corporate Controller, Treasurer
• Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
  Pres, CEO & Chairman
• Thomas Michael Perone J.D., M.B.A.,
  Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Jeffrey A. Rona,
  Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer
• Bart Friedman,
  Lead Independent Director
• Douglas Williams,
  Independent Director
• Karen Bernstein,
  Independent Director
• Barbara Duncan,
  Independent Director
• Jason Tardio,
  Chief Commercial Officer
• Thomas Perone,
  Chief Compliance Officer, General Counsel, Corporate Secretary
• Luke Rosen,
  Sr. VP of Accelerated Devel. & Community Engagement
• Dr. Claude Nicaise,
  Head of R&D
• Dr. Dirk Haasner,
  Sr. VP of Global Manufacturing & CMC QA
• Suzanne K. Wakamoto SHRM-SCP, SPHR,
  Sr. VP of HR
• Lora Pike,
  Sr. Director of Investor Relations & PR
• Jason Tardio M.B.A.,
  Chief Commercial Officer & COO
• Dr. Matthew J. During Ph.D., M.D., DSc, FACP, FRACP,
  Founder & Member of Scientific Advisory Board
• Matthew During,
  Director
• Yaron Werber,
  CBO, CFO, Sec. and Treas.
• Pharmaceutical Co Ltdmillen...,
  
• Ana Ward,
  SVP and General Counsel
• Robert Michael Poole,
  Director
• Pharmaceutical Co Ltd Taked...,
  
• Kevin Joseph Fitzgerald,
  Director
• Margaret A. Alexander,
  President and COO
• Jeffrey A Rona,
  CBFO